BIB holdings: 239 positions
BIB held swaps on Nasdaq Biotechnology Index and Nasdaq Bio Index worth 137.3% of its net assets on Oct 22, 2026. With the 62.4% it holds directly, its exposure is 199.7%.
The largest 100 of 239 positions
| # | Holding | Weight ↓ |
|---|---|---|
| 1 | NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA | 36.14% |
| 2 | NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA | 30.20% |
| 3 | NASDAQ BIO INDEX SWAP BNP PARIBAS | 28.87% |
| 4 | NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL | 19.22% |
| 5 | NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE | 18.31% |
| 6 | Gilead Sciences Inc | 5.40% |
| 7 | Amgen Inc | 5.23% |
| 8 | Vertex Pharmaceuticals Inc | 4.94% |
| 9 | NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG | 4.58% |
| 10 | Regeneron Pharmaceuticals | 3.41% |
| 11 | Moderna Inc | 3.33% |
| 12 | Illumina Inc | 1.67% |
| 13 | Revolution Medicines Inc | 1.65% |
| 14 | Biogen Inc | 1.54% |
| 15 | Alnylam Pharmaceuticals Inc | 1.25% |
| 16 | Royalty Pharma PLC- Cl A | 1.17% |
| 17 | Roivant Sciences Ltd | 1.11% |
| 18 | United Therapeutics Corp | 1.03% |
| 19 | Argenx SE - ADR | 0.98% |
| 20 | Incyte Corp | 0.98% |
| 21 | Guardant Health Inc | 0.90% |
| 22 | Viatris Inc | 0.87% |
| 23 | Insmed Inc | 0.85% |
| 24 | Medpace Holdings Inc | 0.75% |
| 25 | Exelixis Inc | 0.67% |
| 26 | Ascendis Pharma A/S | 0.62% |
| 27 | Neurocrine Biosciences Inc | 0.60% |
| 28 | Halozyme Therapeutics Inc | 0.58% |
| 29 | Jazz Pharmaceuticals PLC | 0.57% |
| 30 | Beone Medicines Ltd-ADR | 0.56% |
| 31 | Bridgebio Pharma Inc | 0.56% |
| 32 | Summit Therapeutics Inc | 0.51% |
| 33 | Tempus Ai Inc-Cl A | 0.46% |
| 34 | Biomarin Pharmaceutical Inc | 0.45% |
| 35 | Madrigal Pharmaceuticals Inc | 0.43% |
| 36 | Biontech SE-ADR | 0.43% |
| 37 | Krystal Biotech Inc | 0.39% |
| 38 | Vaxcyte Inc | 0.38% |
| 39 | Kymera Therapeutics Inc | 0.38% |
| 40 | Sanofi-ADR | 0.37% |
| 41 | Protagonist Therapeutics Inc | 0.37% |
| 42 | Twist Bioscience Corp | 0.37% |
| 43 | Caris Life Sciences Inc | 0.37% |
| 44 | Immunitybio Inc | 0.36% |
| 45 | Cytokinetics Inc | 0.36% |
| 46 | 10X Genomics Inc-Class A | 0.35% |
| 47 | Arrowhead Pharmaceuticals in | 0.34% |
| 48 | Axsome Therapeutics Inc | 0.34% |
| 49 | Spyre Therapeutics Inc | 0.33% |
| 50 | Alkermes PLC | 0.30% |
| 51 | Ionis Pharmaceuticals Inc | 0.30% |
| 52 | Praxis Precision Medicines I | 0.30% |
| 53 | Amneal Pharmaceuticals Inc | 0.29% |
| 54 | Iovance Biotherapeutics Inc | 0.26% |
| 55 | Rhythm Pharmaceuticals Inc | 0.26% |
| 56 | Ligand Pharmaceuticals | 0.25% |
| 57 | Immunovant Inc | 0.25% |
| 58 | Grail Inc | 0.23% |
| 59 | CG Oncology Inc | 0.23% |
| 60 | Cogent Biosciences Inc | 0.22% |
| 61 | Mirum Pharmaceuticals Inc | 0.22% |
| 62 | Kodiak Sciences Inc | 0.22% |
| 63 | Oruka Therapeutics Inc | 0.22% |
| 64 | PTC Therapeutics Inc | 0.22% |
| 65 | Abivax SA-ADR | 0.21% |
| 66 | Scholar Rock Holding Corp | 0.21% |
| 67 | Travere Therapeutics Inc | 0.20% |
| 68 | Erasca Inc | 0.20% |
| 69 | Definium Therapeutics Inc | 0.20% |
| 70 | Crispr Therapeutics AG | 0.20% |
| 71 | Tango Therapeutics Inc | 0.19% |
| 72 | Edgewise Therapeutics Inc | 0.18% |
| 73 | Indivior Pharmaceuticals Inc | 0.17% |
| 74 | Arcutis Biotherapeutics Inc | 0.17% |
| 75 | Relay Therapeutics Inc | 0.17% |
| 76 | Kiniksa Pharmaceuticals Inte | 0.16% |
| 77 | Adaptive Biotechnologies | 0.16% |
| 78 | Genmab A/S -Sp ADR | 0.16% |
| 79 | Veracyte Inc | 0.15% |
| 80 | Abcellera Biologics Inc | 0.15% |
| 81 | Amylyx Pharmaceuticals Inc | 0.15% |
| 82 | Xenon Pharmaceuticals Inc | 0.15% |
| 83 | Acadia Pharmaceuticals Inc | 0.14% |
| 84 | Ideaya Biosciences Inc | 0.14% |
| 85 | Tarsus Pharmaceuticals Inc | 0.14% |
| 86 | Enliven Therapeutics Inc | 0.13% |
| 87 | Denali Therapeutics Inc | 0.12% |
| 88 | Dyne Therapeutics Inc | 0.12% |
| 89 | Disc Medicine Inc | 0.12% |
| 90 | Nurix Therapeutics Inc | 0.11% |
| 91 | Newamsterdam Pharma Co NV | 0.11% |
| 92 | Beam Therapeutics Inc | 0.10% |
| 93 | Adma Biologics Inc | 0.10% |
| 94 | Supernus Pharmaceuticals Inc | 0.10% |
| 95 | MBX Biosciences Inc | 0.10% |
| 96 | Aurinia Pharmaceuticals Inc | 0.09% |
| 97 | Precigen Inc | 0.09% |
| 98 | Fortrea Holdings Inc | 0.09% |
| 99 | Agios Pharmaceuticals Inc | 0.09% |
| 100 | Vericel Corp | 0.09% |
| Cash and other net assets | 37.63% |
Source: ProShares’s daily holdings file. Data as of Oct 22, 2026. Updated each trading day. Report a data error
The book
What this list is
How the list is built
Each weight is the share of net assets the issuer’s own daily file gives, largest first. A swap line’s weight is the exposure it gives the fund, not money the fund paid. Cash and other net assets are in their own row and are not a position. A negative weight is a short or an offsetting contract. A swap’s Tracks column is the name its line gives what it is written on. Names are set in title case where the source used capitals. How books are read.
Weights are as the source states them, largest first.
ETFIQ links to the documents behind every figure; a link is not an endorsement. ETFIQ is an independent publisher and makes no recommendations; every figure is calculated from published data. Standards and sources →
Cite this pageCitation, APA and Markdown
ETFIQ, Holdings of BIB, data as of Oct 22, 2026. https://etfiq.com/funds/bib/holdings/
ETFIQ. (Oct 22, 2026). Holdings of BIB. Retrieved from https://etfiq.com/funds/bib/holdings/
[Holdings of BIB (ETFIQ, Oct 22, 2026)](https://etfiq.com/funds/bib/holdings/)
Free to use with attribution for figures ETFIQ computes; issuer data stays under its owner's terms. The underlying files are at Open data.